56108-25-9

Basic information

• Product Name: 1-Benzyl-4-(p-chlorophenyl)-4-piperidinol
• Synonyms: 1-Benzyl-4-(p-chlorophenyl)-4-piperidinol;1-Benzyl-4-(4-chlorophenyl)-4-piperidinol;N-Benzyl-4-(p-chlorophenyl)-4-piperidinol
• CAS NO: 56108-25-9
• Molecular Formula: C₁₈H₂₀ClNO
• Molecular Weight: 301.81
• Mol File: 56108-25-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 447.5 °C at 760 mmHg
• Flash Point: 224.5 °C
• Appearance: /
• Density: 1.22 g/cm³
• Vapor Pressure: 8.58E-09mmHg at 25°C
• Refractive Index: 1.617
• CAS DataBase Reference: 1-Benzyl-4-(p-chlorophenyl)-4-piperidinol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-(p-chlorophenyl)-4-piperidinol(56108-25-9)
• EPA Substance Registry System: 1-Benzyl-4-(p-chlorophenyl)-4-piperidinol(56108-25-9)

Safety Data

• Hazardous Substances Data: 56108-25-9(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-(p-chlorophenyl)-4-piperidinol is a complex chemical compound with considerable significance in medicinal chemistry and pharmaceutical research. 1-Benzyl-4-(p-chlorophenyl)-4-piperidinol belongs to the class of organic substances known as benzyl alcohols, characterized by one or more hydroxyl groups (-OH) directly correlated to a benzyl group. The precise molecular formula is C19H20ClNO and the molecular weight is 315.82 g/mol. As the name suggests, it contains a benzyl group (a benzene ring with a methyl group), a p-chlorophenyl group (a benzene ring with a chlorine atom), and a piperidinol moiety (a six membered ring with a nitrogen atom and hydroxyl group). Each of these components plays a role in determining the chemical's overall properties, including its solubility, reactivity, and potential biological effects.

InChI:InChI=1/C18H20ClNO/c19-17-8-6-16(7-9-17)18(21)10-12-20(13-11-18)14-15-4-2-1-3-5-15/h1-9,21H,10-14H2

Upstream product

• 106-39-8 bromochlorobenzene 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 4783-65-7 N-benzyl-2-piperidinone 
• 39512-49-7 4-(4-chlorophenyl)-4-hydroxypiperidine 
• 100-39-0 benzyl bromide 
• 41979-39-9 4-piperidone hydrochloride 
• 873-77-8 (4-chlorphenyl)magnesium bromide 

Downstream Products

• 231958-20-6 4-(4-chlorophenyl)-1,2,3,6-tetrahydro-1-(phenylmethyl)-pyridine 
• 324002-50-8 N-benzyl-4-(4-chlorophenyl)-4-fluoropiperidine: 
• 26905-02-2 4-(4-chlorophenyl)piperidine 
• 143866-70-0 N-benzyl-4-(4-chlorophenyl)-piperidine 
• 52-86-8 haloperidol 
• 39512-49-7 4-(4-chlorophenyl)-4-hydroxypiperidine 
• 143682-44-4 3-{4-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-butyl}-1H-indole 
• 1026047-44-8 1-[4-(4-Chloro-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-4-(1H-indol-3-yl)-butan-1-one 
• 51304-61-1 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride 

Relevant articles and documents

Preparation method of flupiperidinol

The invention belongs to the technical field of medicine preparation, and particularly relates to a preparation method of flupiperidinol. The preparation method of the fluoropiperidinol, provided by the invention, comprises the following steps of providing 4-(4-chlorphenyl)-4-piperidinol of which the purity is 99% or above, providing 4-chloro-1-(4-fluorophenyl)butan-1-one of which the purity is more than 99%, mixing the 4-(4-chlorphenyl)-4-piperidinol, 4-chloro-1-(4-fluorophenyl)butan-1-one, an alkaline substance and a catalyst, and carrying out a first substitution reaction to obtain a crudeproduct, and mixing the crude product with an organic solvent, and sequentially carrying out reflux and crystallization to obtain the flupiperidinol. The flupiperidinol prepared according to the preparation method provided by the invention has relatively high yield and purity.

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

Chemokine receptor antagonists and methods of use thereof

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.